From 2010 to 2013, several papers were published with preliminary data regarding the safety and feasibility of CD19-directed CAR-T therapy in patients with advanced follicular lymphoma, refractory chronic lymphocytic leukemia (CLL) and relapsed B-cell acute lymphoblastic leukemia (ALL) [6,7,8,9,10,11]. Here, CD19 is linked to acute lymphoblastic leukemia.